Osteogenic Differentiation

Di-tert-butyl dicarbonate (tBOC) is a covalent modification agent for hydroxyl groups (-OH) on the chitosan molecular chain. Di-tert-butyl dicarbonate selectively modifies chitosan and stabilizes the material structure through hydrophobic encapsulation. Di-tert-butyl dicarbonate reacts with the -OH groups of chitosan to form a hydrophobic layer, and in conjunction with triethylamine (TEA), removes trifluoroacetic acid (TFA) salts produced during the electrospinning process, preserving the nanofiber structure and high porosity of the membrane, and improving the material's cytocompatibility and mineralization-promoting ability. Di-tert-butyl dicarbonate can be used in research in the field of guided bone regeneration (GBR).

Potassium dihydrogen phosphate, AR,99.5% is a potassium salt. Potassium dihydrogen phosphate, AR,99.5% activates NF-κB. Potassium dihydrogen phosphate, AR,99.5% upregulates the expression of dental/osteogenic markers (OCN, DSP/DSPP, OSX, RUNX2, ALP) and enhances the mineralization capacity of human periodontal ligament stem cells. Potassium dihydrogen phosphate, AR,99.5% promotes the proliferation of human periodontal ligament stem cells in logarithmic growth phase. Potassium dihydrogen phosphate, AR,99.5% promotes the growth of somatic embryos of Dendrobium Sonia, increases leaf number, leaf length and fresh weight of tissue-cultured seedlings. Potassium dihydrogen phosphate, AR,99.5% is applicable to periodontal disease-related research.

20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC₅₀ of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis.

Fosfructose is an orally active cyclooxygenase-2 inhibitor and Toll-like receptor 4 modulator. Fosfructose reduces the expression of cyclooxygenase-2, thereby decreasing prostaglandin production. By inhibiting the Toll-like receptor 4 signaling pathway, Fosfructose downregulates LPS-induced adhesion molecule expression. Fosfructose is applicable to research related to ischemic stroke, epilepsy, sepsis, myocardial injury, osteoporosis, and ultraviolet B-induced skin damage.

BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research.

Zinc borate is a bioactive inorganic substance with properties including osteogenic induction, pro-angiogenesis, antioxidation, antimutagenesis and cytotoxicity. In the field of bone tissue engineering, Zinc borate is often incorporated into chitosan scaffolds. By releasing zinc ions and borate ions, Zinc borate induces the differentiation of human dental pulp stem cells into osteoblasts, upregulates the expression of bone-related genes and promotes calcium deposition. Zinc borate also promotes angiogenesis by upregulating key factors such as vascular endothelial growth factor. Zinc borate exhibits antioxidant capacity to scavenge free radicals, and can specifically reduce mutagenicity under specific conditions. Zinc borate reduces the survival rate of mouse fibroblasts, but it can still be used in studies related to bone tissue engineering.

Achyranthes bidentata root extract is a root extract of Achyranthes bidentata that can be used in research on postmenopausal osteoporosis.

Bonesof cervuselaphus extract, derived from red deer bones, has a dual effect of promoting bone formation and inhibiting bone resorption.

Potassium dihydrogen phosphate, for cell culture (Potassium phosphate monobasic, for cell culture) is a cell culture reagent. Potassium dihydrogen phosphate, for cell culture activates NF-κB. Potassium dihydrogen phosphate, for cell culture upregulates the expression of dental/osteogenic markers (OCN, DSP/DSPP, OSX, RUNX2, ALP) and enhances the mineralization capacity of human periodontal ligament stem cells. Potassium dihydrogen phosphate, for cell culture promotes the proliferation of human periodontal ligament stem cells in logarithmic growth phase. Potassium dihydrogen phosphate, for cell culture promotes the growth of somatic embryos of Dendrobium Sonia, increases leaf number, leaf length and fresh weight of tissue-cultured seedlings. Potassium dihydrogen phosphate, for cell culture is applicable to periodontal disease-related research.

6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K⁺ channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K⁺ channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration.

Neridronate is a bisphosphonate. Bisphosphonates initiate the Apoptotic process. Neridronate sodium reduces the levels of bone resorption, bone turnover markers, the degree of back pain, and the risk of fractures. Neridronate inhibits capillary tube formation. Neridronate itself has weak anticancer activity, but liposomal encapsulation enhances this activity. Neridronate can be used in research related to demineralizing metabolic bone diseases, thalassemia-associated osteoporosis, chronic inflammatory diseases, cancer, and osteogenesis imperfecta.

Netoglitazone (MCC-555) is an orally active PPARγ ligand with an EC₅₀ of 8 μM. Netoglitazone mediates cell type-specific functional regulation, and modulates the transcriptional activity of PPARγ as a full agonist, partial agonist or antagonist. Netoglitazone induces adipogenesis, inhibits osteoblastogenesis, alters the weight of extramedullary fat depots and enhances insulin sensitivity. Netoglitazone reduces blood glucose levels. Netoglitazone can be used in research related to type 2 diabetes and non-insulin-dependent diabetes mellitus.

Methyl (E)-cinnamate (Methyl (E)-3-phenylpropenoate) is a natural flavor compound with anti-inflammatory properties found in Alpinia katsumadai Hayata. Methyl (E)-cinnamate induces apoptosis via reduced anti-apoptotic protein expression, increased TUNEL-positive cells, and apoptotic morphological changes. Methyl (E)-cinnamate can be used for the research of abnormalities of osteoblast function in bone diseases.

Anhydrous calcium sulfate (97%) serves as an oil-based drilling fluid additive and an osteogenic material. Anhydrous calcium sulfate (97%) increases the plastic viscosity, yield point, apparent viscosity and gel strength of oil-based drilling fluids. Anhydrous calcium sulfate (97%) upregulates the expression of bone-related genes FOSL1, RUNX2 and SPP1. Anhydrous calcium sulfate (97%) significantly affects the behavior of dental pulp stem cells, enhancing their proliferation, differentiation and matrix deposition.

Necrostatin-7 (Nec-7) is a Necroptosis inhibitor with an EC₅₀ of 10.6 μM. Necrostatin-7 inhibits signal transduction from RANK to NFATc1 without affecting the activation of MAPK or NF-κB. Necrostatin-7 suppresses the expression levels of Acp5, Atp6v0d2, Ctsk and Dcstamp. Necrostatin-7 reduces myocardial infarction size, ameliorates adverse left ventricular remodeling, decreases myocardial wall stress, reduces the amount and length of scar tissue, and improves left ventricular function. Necrostatin-7 exerts cardioprotective effects in a rat model of permanent coronary artery occlusion. Necrostatin-7 can be used in research related to osteolytic bone diseases and myocardial infarction.

Q-Peptide is an angiopoietin-1 derived peptide (QHREDGS). Q-Peptide interacts with β1-integrin, binds to integrins on the surface of osteoblasts, and serves as an acyl donor substrate for Streptomyces mobaraensis transglutaminase. Q-Peptide activates Akt, MAPKp42/44, ILK, ERK1/2, and downregulates caspase-3/7. Q-Peptide inhibits cell apoptosis, enhances cell adhesion and migration, and promotes osteoblast differentiation, bone matrix deposition and mineralization. Q-Peptide can be used in studies related to myocardial infarction, bone regeneration, diabetic wound repair and human induced pluripotent stem cells.

GLI-IN-1 is a potent, PKC-dependent Gli inhibitor. GLI-IN-1 binds to the C1 domain of PKC, forms hydrogen-bonding interactions with the M239 residue, and mediates the inhibition of downstream Gli via a PKC-mediated, Smoothened-independent mechanism. GLI-IN-1 can be used in studies of Gli-driven cancers and osteogenic differentiation.

GGTI-2166 is a geranylgeranyltransferase I (GGTase I) inhibitor. GGTI-2166 blocks geranylgeranylation modification of target proteins. GGTI-2166 inhibits RANKL- or TNF-α-induced pre-osteoclast formation and TRAP activity. GGTI-2166 is applicable to research on osteoclast differentiation.

C14-Tri-LAN-Gly is a highly selective and potent NOD1 agonist. C14-Tri-LAN-Gly activates NOD1. C14-Tri-LAN-Gly inhibits the expression of cleaved-caspase3. C14-Tri-LAN-Gly upregulates A20 expression. C14-Tri-LAN-Gly protects mice from lethal hepatitis by inhibiting hepatocyte Apoptosis. C14-Tri-LAN-Gly inhibits osteoblastogenesis and promots osteoclastogenesis.

Neridronate sodium is a bisphosphonate. Bisphosphonates initiate the Apoptotic process. Neridronate sodium reduces the levels of bone resorption, bone turnover markers, the degree of back pain, and the risk of fractures. Neridronate sodium inhibits capillary tube formation. Neridronate sodium itself has weak anticancer activity, but liposomal encapsulation enhances this activity. Neridronate sodium can be used in research related to demineralizing metabolic bone diseases, thalassemia-associated osteoporosis, chronic inflammatory diseases, cancer, and osteogenesis imperfecta.